


CLAIMS:

1. (Original) A compound of formula (I),



(I)

or a pharmaceutically acceptable derivative thereof, wherein:

Het represents 2-pyridinyl or 2-pyrimidinyl;

R¹ represents H, C₁₋₃ alkyl or a nitrogen-containing heterocyclic ring having 5 or 6 ring atoms;

R² represents H, benzyl or C₁₋₃ alkyl; and

R³ represents H, methyl, methoxy or chloro.

2. (Currently amended) A compound according to claim 1, or a pharmaceutically acceptable derivative thereof, wherein Het represents 2-pyridinyl.
3. (Currently amended) A compound according to claim 1 ~~or claim 2~~, or a pharmaceutically acceptable derivative thereof, wherein R¹ represents 1,2,3-triazolyl.
4. (Currently amended) A compound according to claim 1 ~~any of claims 1 to 3~~, or a pharmaceutically acceptable derivative thereof, wherein R² represents H or methyl.
5. (Currently amended) A compound according to claim 1 ~~any of claims 1 to 4~~, or a pharmaceutically acceptable derivative thereof, wherein R³ represents chloro.
6. (Currently amended) A compound as claimed in claim 1 ~~or claim 4~~, or a pharmaceutically acceptable derivative thereof, wherein at least one of R¹, R² and R³ represents a group other than H.
7. (Currently amended) A compound as claimed in claim 1, or a pharmaceutically acceptable derivative thereof, wherein R¹ represents 1,2,3-triazolyl and/or R³ represents chloro.
8. (Original) A compound according to claim 1, selected from
 2-{4-[4-(2-Ethyl-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-pyrimidine;
 2-{4-[5-Methyl-4-(2-propyl-phenyl)-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-pyrimidine;
 2-{4-[4-(2-Isopropyl-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-pyrimidine

4-(5-Morpholin-4-ylmethyl-4-phenyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
 4-(5-Butyl-4-phenyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
 4-(4-Phenyl-5-piperidin-1-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
 4-(5-Methyl-4-phenyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
 4-[4-(4-Methoxy-2-methyl-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
 4-[4-(4-Chloro-2-methyl-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
 4-(5-Methyl-4-o-tolyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
 4-[4-(4-Chloro-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
 4-[4-(4-Methoxy-phenyl)-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
 4-[4-(4-Methoxy-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
 4-(4-o-Tolyl-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
 4-[4-(4-Chloro-2-methyl-phenyl)-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
 4-(4-Phenyl-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
 4-[4-(4-Chloro-phenyl)-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
 4-(5-Methyl-4-p-tolyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
 4-[4-(2,4-Dimethyl-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
 4-[4-(4-Chloro-2-methyl-phenyl)-5-morpholin-4-ylmethyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl; and
 pharmaceutically acceptable derivatives thereof.

9. (Currently amended) The use of a compound according to claim 1 any of claims 1 to 8, or a pharmaceutically acceptable derivative thereof, as a medicament.

10. (Currently amended) A method of treatment of a disorder selected from anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittlemerchz, preclampsia, premature ejaculation, premature (preterm) labor and Raynaud's disease, comprising administering a therapeutically effective amount of a compound according to claim 1 any of claims 1 to 8, or a pharmaceutically acceptable derivative thereof, to a patient suffering from such a disorder.
11. (Original) A method according to claim 10 wherein the disorder is dysmenorrhoea (primary or secondary).
12. (Original) A method according to claim 11 wherein the disorder is primary dysmenorrhoea.
13. (Currently amended) The use of a compound according to claim 1 any of claims 1 to 8, or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the treatment of a disorder selected from anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittlemerchz, preclampsia, premature ejaculation, premature (preterm) labor and Raynaud's disease.
14. (Original) Use according to claim 13 wherein the disorder is dysmenorrhoea (primary and secondary).
15. (Original) Use according to claim 14 wherein the disorder is primary dysmenorrhoea.
16. (Currently amended) A pharmaceutical formulation including a compound according to claim 1 any of claims 1 to 8 or a pharmaceutically acceptable derivative thereof, together with a pharmaceutically acceptable excipients, diluent or carrier;
17. (Currently amended) A pharmaceutical product containing a V1a antagonist according to claim 1 any of claims 1 to 8 or a pharmaceutically acceptable derivative thereof in combination with a compound selected from (a) an oral contraceptive, (b) a PDE5 inhibitor, (c) an NO donor, (d) L-arginine, or (e) a COX inhibitor, as a combined preparation for simultaneous, separate or sequential use in the treatment of dysmenorrhoea.